Abselion are a Cambridge university spin out developing a benchtop tool to automate binding assays. Specifically, antibody and viral vector quantification assays in crude samples. The Amperia system streamlines workflows in bioprocessing by giving users the ability to quantify material from their bioreactors at line, in real time. Amperia is set to launch in May 2024 and our early adopter scheme gives researchers in the industry the chance to validate this compact and powerful new product in their own labs. 

Get Involved with the Advanced Therapies Congress


To sponsor or exhibit

Ashlea Foster
+44 208 164 3032



To speak

Ila Dickinson
+44 207 092 1150